JP2013538566A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538566A5
JP2013538566A5 JP2013523643A JP2013523643A JP2013538566A5 JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5 JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
dom7h
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/063999 external-priority patent/WO2012020143A1/en
Publication of JP2013538566A publication Critical patent/JP2013538566A/ja
Publication of JP2013538566A5 publication Critical patent/JP2013538566A5/ja
Pending legal-status Critical Current

Links

JP2013523643A 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体 Pending JP2013538566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37339710P 2010-08-13 2010-08-13
US61/373,397 2010-08-13
PCT/EP2011/063999 WO2012020143A1 (en) 2010-08-13 2011-08-12 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
JP2013538566A JP2013538566A (ja) 2013-10-17
JP2013538566A5 true JP2013538566A5 (cg-RX-API-DMAC7.html) 2014-09-18

Family

ID=44582954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523643A Pending JP2013538566A (ja) 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体

Country Status (4)

Country Link
US (2) US9012609B2 (cg-RX-API-DMAC7.html)
EP (1) EP2603522A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013538566A (cg-RX-API-DMAC7.html)
WO (1) WO2012020143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317315A (zh) 2009-02-11 2012-01-11 诺维信生物制药丹麦公司 白蛋白变体和缀合物
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
US20160222087A1 (en) * 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
PL3374392T3 (pl) * 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
KR102533456B1 (ko) 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
WO2018134234A1 (en) 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
DK3571225T3 (da) 2017-01-17 2024-11-04 Ablynx Nv Forbedrede serumalbuminbindere
HRP20250319T1 (hr) 2017-02-16 2025-05-09 Sonnet BioTherapeutics, Inc. Fuzijski proteini s domenom za vezanje na albumin
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
US5658739A (en) 1994-05-10 1997-08-19 The Regents Of The University Of California Method for characterization of the fine structure of protein binding sites
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2502647A1 (en) 2002-10-18 2004-04-29 The Regents Of The University Of California Methods for crystallographic structure determination employing hydrogen exchange analysis
EP1737962B1 (en) 2004-03-24 2010-09-01 Domantis Limited Gas1 universal leader
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
MX2009013137A (es) * 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
EA023031B1 (ru) 2007-11-30 2016-04-29 Глаксо Груп Лимитед Антиген-связывающая конструкция и ее применение
BRPI0922772B1 (pt) 2008-12-05 2021-09-08 Glaxo Group Limited Domínio variável único de imunoglobulina e polipeptídeos isolados
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
PE20120170A1 (es) 2009-02-19 2012-03-21 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas
AR075505A1 (es) * 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero mejoradas
JP2012532620A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
CN102666586A (zh) * 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants

Similar Documents

Publication Publication Date Title
JP2013538566A5 (cg-RX-API-DMAC7.html)
CN110191896B (zh) 改进的血清白蛋白结合物
RU2577228C2 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2013529080A5 (cg-RX-API-DMAC7.html)
JP2016539096A5 (cg-RX-API-DMAC7.html)
JP2017520575A5 (cg-RX-API-DMAC7.html)
HRP20161043T1 (hr) Ljudska antitijela visokog afiniteta u odnosu na ljudski angiopoietin-2
RS66173B1 (sr) Poboljšana veziva serumskog albumina
JP2010526028A5 (cg-RX-API-DMAC7.html)
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
RU2018113505A (ru) Il-8-связывающие антитела и их применения
RU2019123112A (ru) Анти-il-5 антитела
IL266907B1 (en) Improved serum albumin binding immunoglobulin single variable domains
CN104245736B (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
RU2017144098A (ru) Гетеродимеризованный полипептид
JP2017506075A5 (cg-RX-API-DMAC7.html)
JP2013519721A5 (cg-RX-API-DMAC7.html)
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
CN115397852B (zh) 工程化抗il-2抗体
JP2009539349A5 (cg-RX-API-DMAC7.html)
JP2015530983A5 (cg-RX-API-DMAC7.html)
JP2021530207A (ja) 二重特異性抗体及びその使用
JP2018509887A5 (cg-RX-API-DMAC7.html)
JP2014534237A5 (cg-RX-API-DMAC7.html)
JP2014530001A5 (cg-RX-API-DMAC7.html)